Stock listing
BOATS:REPL Replimune Group, Inc. Stock
US listing (BOATS) of Replimune Group, Inc. · home listing NASDAQ:REPL
Follow Replimune Group, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:REPL
$17.61 USD +0.22 (+1.3%)
Close on Oct 30, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:REPL
- Day range
- $16.64 – $18.27 USDOct 30, 2026
- Volume
- 3.85M sharesOct 30, 2026
- Market cap
- $1.66B USDAt the close on Oct 30, 2026 · price × 94.22M shares outstanding
- 52-week range
- $1.50 – $18.27 USDLowest and highest trades, Oct 31, 2025 – Oct 30, 2026
- Traded on an average day
- $45.61M USDMedian day 2.18M shares · 1 day with no trades · last 3 months, Jul 30, 2026 – Oct 30, 2026
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:REPL · Home | $17.61 USD | +0.22 (+1.3%) | 3,851,718 | $17.49 | $18.27 | $16.64 | $17.39 | Close on Oct 30, 2026 |
| Frankfurt:7R8 | €14.79 EUR | +3.645 (+32.7%) | — | €15.26 | €15.82 | €14.79 | €11.15 | Close on Oct 30, 2026 |
Daily closes
Last 3 months, Jul 30, 2026 – Oct 30, 2026 · NASDAQ:REPL · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $17.61 | +0.22 | +1.3% | $17.49 | $18.27 | $16.64 | 3,851,718 | |
| $17.39 | +1.33 | +8.3% | $16.27 | $17.78 | $16.20 | 5,139,262 | |
| $16.06 | +3.01 | +23.1% | $12.96 | $16.75 | $12.50 | 7,277,843 | |
| $13.05 | +0.58 | +4.7% | $12.45 | $13.16 | $12.21 | 4,297,897 | |
| $12.47 | +1.01 | +8.8% | $11.56 | $12.57 | $11.36 | 2,044,627 | |
| $11.46 | -0.53 | -4.4% | $11.92 | $11.92 | $11.43 | 1,905,000 | |
| $11.99 | +0.27 | +2.3% | $11.70 | $12.01 | $11.53 | 1,760,500 | |
| $11.72 | +0.30 | +2.6% | $11.37 | $12.05 | $11.31 | 2,202,100 | |
| $11.42 | +0.37 | +3.3% | $11.04 | $11.69 | $11.00 | 1,388,900 | |
| $11.05 | +0.19 | +1.7% | $11.03 | $11.23 | $10.67 | 1,539,700 | |
| $10.86 | -0.89 | -7.6% | $11.73 | $11.73 | $10.81 | 1,710,800 | |
| $11.75 | +0.36 | +3.2% | $11.32 | $11.86 | $11.23 | 1,613,600 | |
| $11.39 | -0.72 | -5.9% | $12.05 | $12.37 | $11.37 | 1,862,800 | |
| $12.11 | -0.96 | -7.3% | $12.91 | $12.93 | $12.07 | 1,631,200 | |
| $13.07 | -0.35 | -2.6% | $13.21 | $13.56 | $12.97 | 1,161,500 | |
| $13.42 | +0.38 | +2.9% | $12.96 | $13.44 | $12.79 | 2,022,800 | |
| $13.04 | -0.16 | -1.2% | $13.18 | $13.46 | $12.85 | 1,747,700 | |
| $13.20 | -0.05 | -0.4% | $13.14 | $13.60 | $13.01 | 1,647,200 | |
| $13.25 | +0.10 | +0.8% | $13.17 | $13.51 | $12.87 | 2,617,000 | |
| $13.15 | +0.08 | +0.6% | $13.14 | $13.29 | $12.51 | 2,275,800 | |
| $13.07 | -0.38 | -2.8% | $13.69 | $13.83 | $12.80 | 1,302,900 | |
| $13.45 | +0.21 | +1.6% | $13.26 | $13.59 | $13.06 | 2,517,500 | |
| $13.24 | +0.24 | +1.8% | $12.99 | $13.66 | $12.65 | 3,081,600 | |
| $13.00 | +0.44 | +3.5% | $12.44 | $13.42 | $12.35 | 4,365,000 | |
| $12.56 | +0.20 | +1.6% | $12.15 | $12.76 | $12.07 | 1,966,400 | |
| $12.36 | -0.24 | -1.9% | $12.63 | $12.80 | $12.30 | 1,647,300 | |
| $12.60 | -0.36 | -2.8% | $12.87 | $12.88 | $12.07 | 2,581,700 | |
| $12.96 | -0.51 | -3.8% | $13.50 | $13.60 | $12.68 | 1,887,500 | |
| $13.47 | +0.60 | +4.7% | $12.93 | $13.64 | $12.80 | 1,529,900 | |
| $12.87 | -0.20 | -1.5% | $13.11 | $13.28 | $12.76 | 1,461,700 | |
| $13.07 | +0.20 | +1.6% | $13.02 | $13.20 | $12.68 | 2,149,700 | |
| $12.87 | -0.09 | -0.7% | $13.15 | $13.40 | $12.62 | 1,294,700 | |
| $12.96 | -0.07 | -0.5% | $13.10 | $13.19 | $12.71 | 1,810,700 | |
| $13.03 | -0.08 | -0.6% | $12.98 | $13.06 | $12.46 | 2,154,200 | |
| $13.11 | +0.19 | +1.5% | $12.90 | $13.65 | $12.79 | 2,350,700 | |
| $12.92 | -0.32 | -2.4% | $13.33 | $13.74 | $12.40 | 4,085,000 | |
| $13.24 | -1.21 | -8.4% | $14.47 | $14.47 | $13.21 | 3,645,100 | |
| $14.45 | -0.32 | -2.2% | $14.54 | $14.76 | $14.30 | 1,074,800 | |
| $14.77 | -0.27 | -1.8% | $14.90 | $14.99 | $14.61 | 1,494,200 | |
| $15.04 | -0.25 | -1.6% | $15.22 | $15.33 | $14.80 | 908,700 | |
| $15.29 | -0.69 | -4.3% | $15.99 | $16.03 | $15.02 | 1,353,600 | |
| $15.98 | +0.31 | +2.0% | $15.65 | $16.33 | $15.50 | 1,989,000 | |
| $15.67 | +0.37 | +2.4% | $15.24 | $15.71 | $14.97 | 1,778,700 | |
| $15.30 | -0.20 | -1.3% | $15.36 | $15.52 | $14.90 | 1,700,600 | |
| $15.50 | -0.10 | -0.6% | $15.40 | $15.87 | $15.40 | 2,386,700 | |
| $15.60 | -0.28 | -1.8% | $15.76 | $16.15 | $15.56 | 1,670,700 | |
| $15.88 | +0.08 | +0.5% | $15.60 | $15.99 | $15.05 | 2,374,900 | |
| $15.80 | +1.09 | +7.4% | $14.63 | $15.89 | $14.59 | 3,133,800 | |
| $14.71 | -0.06 | -0.4% | $14.63 | $15.04 | $14.11 | 2,081,100 | |
| $14.77 | +0.72 | +5.1% | $13.88 | $14.98 | $13.81 | 2,969,300 | |
| $14.05 | -0.76 | -5.1% | $14.55 | $14.77 | $13.92 | 4,295,900 | |
| $14.81 | -0.77 | -4.9% | $15.17 | $15.64 | $14.73 | 3,441,400 | |
| $15.58 | +0.95 | +6.5% | $14.60 | $15.62 | $14.50 | 2,244,800 | |
| $14.63 | -0.34 | -2.3% | $14.65 | $14.69 | $14.05 | 3,735,000 | |
| $14.97 | -0.22 | -1.4% | $15.19 | $15.39 | $14.69 | 2,398,900 | |
| $15.19 | -0.05 | -0.3% | $15.00 | $15.71 | $14.98 | 3,220,700 | |
| $15.24 | +1.59 | +11.6% | $13.62 | $15.68 | $13.62 | 8,272,500 | |
| $13.65 | -0.02 | -0.1% | $13.76 | $14.14 | $13.20 | 4,767,000 | |
| $13.67 | +1.61 | +13.3% | $12.64 | $14.12 | $12.27 | 8,860,000 | |
| $12.06 | -0.80 | -6.2% | $13.00 | $13.40 | $11.42 | 8,914,100 | |
| $12.86 | +1.03 | +8.7% | $11.78 | $13.90 | $11.58 | 7,281,400 | |
| $11.83 | -0.09 | -0.8% | $11.96 | $12.35 | $11.50 | 2,862,100 | |
| $11.92 | +0.01 | +0.1% | $12.67 | $13.86 | $11.50 | 6,086,200 | |
| $11.91 | +0.71 | +6.3% | $11.00 | $12.60 | $10.13 | 11,771,300 | |
| $11.20 | +5.79 | +107.0% | $11.38 | $12.50 | $9.43 | 33,629,900 | |
| $5.41 | 0.00 | 0.0% | $5.41 | $5.41 | $5.41 | 0 |
- Ticker
- BOATS:REPL
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- BOATS
- Currency
- USD
What changed lately
Latest news release · Oct 28, 2026
Replimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate Update
Latest earnings call · Oct 28, 2026
Replimune Group (NASDAQ:REPL) Q2 2027 Earnings Call
Replay and transcript
Latest deck · Aug 6, 2026
Corporate Update (August 2026)
Corporate update · 30 slides
Calls
Replays
Replimune Group (NASDAQ:REPL) Q2 2027 Earnings Call
Wed, Oct 28, 2026 · 8:00 AM ET
Watch TranscriptReplimune Group (NASDAQ:REPL) Q4 2025 Earnings Call
Thu, May 22, 2025 · 8:00 AM ET
Watch Transcript
Latest news
Replimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate Update
Oct 28, 2026
Closed $16.06 (+23.1%) on Oct 28, 2026
Replimune to Report the Fiscal Second Quarter 2027 Financial Results and Provide Corporate Update on October 28, 2026
Oct 22, 2026
Closed $11.99 (+2.3%) on Oct 22, 2026
Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma
Oct 1, 2026
Closed $13.07 (-2.8%) on Oct 2, 2026
Replimune to Present at the Cantor Global Healthcare Conference 2026
Sep 3, 2026
Closed $15.29 (-4.3%) on Sep 3, 2026
Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update
Aug 14, 2026
Closed $14.97 (-1.4%) on Aug 14, 2026
Replimune Announces Pricing of $150 Million Underwritten Offering
Aug 10, 2026
Closed $13.67 (+13.3%) on Aug 10, 2026
Replimune Announces FDA Accelerated Approval of TUDRIQEVTM in Combination with Nivolumab for Unresectable Advanced Cutaneous Melanoma After Progression on an anti-PD-1 Based Regimen
Aug 6, 2026
Closed $12.06 (-6.2%) on Aug 7, 2026
Replimune Announces Favorable Outcome of FDA's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in Advanced Melanoma
Jul 30, 2026
Closed $11.20 (+107.0%) on Jul 31, 2026
Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update
Jun 29, 2026
Closed $11.20 (-3.7%) on Jun 29, 2026
Replimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced Melanoma
Jun 26, 2026
Closed $11.63 (+4.5%) on Jun 26, 2026
Financings
Public offering of common stock
Aug 14, 2026
Closed: US$150M raised · US$12.06 a share · Leerink Partners +2
Dealers: Leerink Partners (co-lead), J.P. Morgan (co-lead), Cantor (co-lead)
Use of proceeds: Support the commercial launch of TUDRIQEV and the ongoing IGNYTE-3 confirmatory trial
Decks
Corporate Update (August 2026)
Corporate update · 30 slides · Aug 6, 2026
Technical Presentation (July 2026)
Technical · 64 slides · Jul 30, 2026
JPM Healthcare Conference 2026
Conference · 30 slides · Jan 14, 2026
Technical Presentation (June 2024)
Technical · 27 slides · Jun 6, 2024
Replimune Group, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 18 in the last 12 months · 139 in all · newest Oct 28, 2026 · oldest 2019
- Calls
- 2 calls with a replay · 2 with a transcript · latest Oct 28, 2026
- Decks
- 9 decks · latest Aug 6, 2026
Where Replimune Group, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:REPL · Home listing | NASDAQ | United States | USD |
| gettex:7R8 | gettex | Germany | EUR |
| LS Exchange:A2JQN1 | LS Exchange | Germany | EUR |
| BOATS:REPL · This page | BOATS | United States | USD |
| Lang & Schwarz:A2JQN1 | Lang & Schwarz | Germany | EUR |
| Stuttgart:7R8 | Stuttgart | Germany | EUR |
| Tradegate:7R8 | Tradegate | Germany | EUR |
| Frankfurt:7R8 | Frankfurt | Germany | EUR |
| Hamburg:7R8 | Hamburg | Germany | EUR |
| Munich:7R8 | Munich | Germany | EUR |
| Dusseldorf:7R8 | Dusseldorf | Germany | EUR |
Log in to ask 6ix AI your own questions about Replimune Group, Inc.